about our products
Portage is a catalyst of immuno-oncology research and development, with subsidiary companies developing immunotherapies to augment response in immunogenic tumors, and help initiate response in non-immunogenic tumors. Our portfolio includes antibodies, small molecules and protein therapeutics delivered by novel intratumoral formulations, nanoparticles, liposomes, and virus-like particles.
There is a significant unmet need to better serve patients who do not respond to existing checkpoints, and we seek subsidiaries that develop novel treatments to improve responses to these therapies.
